BridgeBio
BridgeBio Oncology Therapeutics
Quick answer
BridgeBio is a pharma company (BBOT) headquartered in SOUTH SAN FRANCISCO, CA, USA with 24 tracked pipeline programs.
Pipeline (24)
AG10
Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
1 trials projectALXN2060
Symptomatic Transthyretin Amyloid Cardiomyopathy
1 trials projectAcoramidis
Amyloidosis
3 trials projectAcoramidis
Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
1 trials projectAcoramidis (AG10)
Amyloidosis in Transthyretin (TTR)
1 trials projectAcoramidis (AG10)
Amyloid Cardiomyopathy, Transthyretin-Related
1 trials projectBGJ398
Advanced Cholangiocarcinoma
1 trials projectEncaleret
Autosomal Dominant Hypocalcemia Type 1 (ADH1)
1 trials projectEncaleret
Autosomal Dominant Hypocalcemia (ADH)
2 trials projectInfigratinib
Upper Tract Urothelial Carcinomas
1 trials projectInfigratinib 0.25 mg/kg/day
Achondroplasia
1 trials projectinfigratinib 0.128 mg/kg/day
Hypochondroplasia
1 trials projectAG10
Familial ATTR-CM (ATTRm-CM, or FAC)
1 trials projectAG10
Amyloid Cardiomyopathy
1 trials projectBGJ398 (infigratinib)
Advanced Cholangiocarcinoma
1 trials projectInfigratinib
Hypochondroplasia
1 trials projectInfigratinib
Achondroplasia
1 trials projectInfigratinib 0.016 mg/kg
Achondroplasia
1 trials projectInfigratinib is provided as a single dose of minitablets for oral administration
Achondroplasia
1 trials projectPTR-01
Recessive Dystrophic Epidermolysis Bullosa
1 trials projectVT30
Venous Malformation
1 trials projectencaleret
Post-Surgical Hypoparathyroidism
1 trials projectAG10 oral tablet
Amyloid Cardiomyopathy, Transthyretin-Related
1 trials projectBBO-10203
Solid Tumor, Adult
1 trials